A First-in-Human Phase I, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of Anti-BAFFR mAb, ESG206 in Subjects With B-cell Lymphoid Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 12
- 主要终点
- Percentage of Participants Experiencing Any Treatment Emergent Adverse Events
研究概览
简要总结
This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B lymphoid malignancies.
详细描述
This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The study will follow a modified 3+3 dose escalation scheme. Dose escalation will continue until identification of MTD or the predicted efficacy dose in the event that a MTD is not identified due to paucity of DLTs. Toxicity including dose-limiting toxicity (DLT) observed in Cycle 1 of the first 28 days will be used to determine escalation to the next dose level as described below.
Five dose levels are planned. Dose choosing will be determined by the SMC and the sponsor based on the pharmacokinetics, tolerability and preliminary antitumor activities, as well as other available data.
Subjects will be monitored for safety, tolerability, and efficacy throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent for the trial.
- •Male or female and at least 18 years of age.
- •Subjects must have a histologically confirmed (or documented), incurable B-cell hematologic malignancy that had progressed despite standard of care therapy and for which there was no alternative therapy of proven benefit or no effective standard therapy is available or tolerable.
- •Measurable or evaluable Disease.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Subject must have adequate organ function.
排除标准
- •Has had prior chemotherapy, targeted therapy, immunotherapy or any other agents used as systemic treatment for cancer, within 14 days before first dosing.
- •Had major surgery within 4 weeks before first dosing.
- •Had undergone an autologous stem cell transplant within 100 days before first dosing.
- •Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, or renal disease).
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product or excipients.
- •Pregnant or breastfeeding women.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
研究组 & 干预措施
ESG206 dose level 1
ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle.
干预措施: ESG206 (Drug)
ESG206 dose level 2
ESG206 will be administered intravenously at dose level 2 every two weeks in a 28-day cycle.
干预措施: ESG206 (Drug)
ESG206 dose level 3
ESG206 will be administered intravenously at dose level 3 every two weeks in a 28-day cycle.
干预措施: ESG206 (Drug)
ESG206 dose level 4
ESG206 will be administered intravenously at dose level 4 every two weeks in a 28-day cycle.
干预措施: ESG206 (Drug)
ESG206 dose level 5
ESG206 will be administered intravenously at dose level 5 every two weeks in a 28-day cycle.
干预措施: ESG206 (Drug)
结局指标
主要结局
Percentage of Participants Experiencing Any Treatment Emergent Adverse Events
时间窗: First dose date up to last dose plus 30 days
Treatment-emergent adverse events (TEAEs) were defined as: Any AE that happens after treatment initiation,.or AE that was present at time of treatment initiation but worsened after treatment initiation, or AE that was present and resolved prior to treatment and reappeared after treatment initiation after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.
次要结局
- Progression-free Survival (PFS)(Up to 20 months)
- ADA(Up to 20 months)
- AUC0-inf(Up to 20 months)
- Tmax(Up to 20 months)
- T1/2(Up to 20 months)
- Overall Response (OR)(Up to 20 months)
- Cmax(Up to 20 months)